Most significant clincal trials of 2024

2024 saw significant clinical trial results, including successful Phase III trials for Gilead's HIV PReP lenacapavir, Scholar Rock's SMA drug apitegromab, and Lilly's obesity drug Zepbound. However, failures included Amylyx's ALS drug Relyvrio and Pfizer's DMD gene therapy. GlobalData reports most trials were Phase I (40.92%) and II (36.28%), with 7,089 completions in 2024.

Related Clinical Trials

Open-label Extension for Phase 3 Clinical Trials of Simufilam
AMX0035 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease
A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide in Adolescent Girls and Young Women at Risk of HIV Infection
Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight With Weight Related Comorbidities
PTI-125 for Mild-to-moderate Alzheimer's Disease Patients
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Study of Lenacapavir for HIV Pre-Exposure Prophylaxis in People Who Are at Risk for HIV Infection
Efficacy and Safety of Apitegromab in Patients With Later-Onset Spinal Muscular Atrophy Treated With Nusinersen or Risdiplam
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Simufilam 100 Mg for Mild-to-Moderate Alzheimer's Disease
Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy

Related News

clinicaltrialsarena.com
Most significant clincal trials of 2024

2024 saw significant clinical trial results, including successful Phase III trials for Gilead's HIV PReP lenacapavir, Scholar Rock's SMA drug apitegromab, and Lilly's obesity drug Zepbound. However, failures included Amylyx's ALS drug Relyvrio and Pfizer's DMD gene therapy. GlobalData reports most trials were Phase I (40.92%) and II (36.28%), with 7,089 completions in 2024.

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy